Allogeneic blood cell transplants for haematological malignancy: Preliminary comparison of outcomes with bone marrow transplantation

Bone Marrow Transplantation

Volumn 17, Issue 5, 1996, Pages 703-708

  Russell, J A ^a,b,c   Brown, C ^a,b   Bowen, T ^c   Luider, J ^a   Ruether, J D ^a,b   Stewart, D ^a,b   Chaudhry, A ^a,b   Booth, K ^c   Jorgenson, K ^c   Coppes, M J ^c   Turner, A R ^d   Larratt, L ^d   Desai, S ^d   Poon, M C ^a   Klassen, J ^a  

^a FOOTHILLS HOSPITAL   (Canada)

^b TOM BAKER CANCER CENTRE   (Canada)

^c ALBERTA CHILDREN'S HOSPITAL   (Canada)

^d CROSS CANCER INSTITUTE   (Canada)

Author keywords

Allogeneic; Blood cell transplants

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOGRAFT; ARTICLE; BLOOD TRANSFUSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ERYTHROCYTE; FEMALE; GRAFT VERSUS HOST REACTION; GRANULOCYTE; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RISK; SCHOOL CHILD; SIBLING; STEM CELL TRANSPLANTATION; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BLOOD CELL COUNT; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; FAMILY; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; LEUKAPHERESIS; LIVING DONORS; MALE; MIDDLE AGED; TRANSPLANTATION, HOMOLOGOUS;

EID: 15844394102     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Bender JG, To LB, Williams S. Schwarzberg LS. Defining a therapeutic dose of peripheral blood stem cells, J Hematother 1992; 1: 329-341.
2. Sheridan WP, Begley GC. Juttner CA et al. Effect of peripheral blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339: 640-644.
3. Dicke KA, Hood D, Hanks S. Peripheral blood stem cell collection after mobilization with intensive chemotherapy and growth factors. J Hematother 1993; 2: 141-144.
4. To LB, Roberts MM, Haylock DN et al. Comparison of haematological recovery times and supportive care requirements of autologous phase peripheral blood cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplants 1992; 9: 277-284.
5. Rice A, Reiffers J. Mobilized stem cells: immunophenotyping and functional characteristics. J Hematother 1993; 1: 19-26.
6. Baumann I, Testa NG, Lange C et al. Haemopoietic cells mobilised into the circulation by lenograstim as alternative to bone marrow for allogeneic transplants. Lancet 1993; 341: 369 (letter).
7. Matsunaga T, Sakami S, Kongo Y et al. Recombinant human granulocyte colony-stimulating factor can mobilise sufficient amounts of peripheral blood stem cells in healthy volunteers for allogeneic transplantation. Bone Marrow Transplant 1993; 11: 103-108.
8. Dreger P, Suttorp M, Haferlach T et al. Allogeneic granulocyte colony-stimulating factor mobilised peripheral blood progenitor cells for treatment of engraftment failure after bone marrow transplantation. Blood 1993; 81: 1404-1409.
9. Russell NH, Hunter A, Rogers S et al. Peripheral blood stem cells as an alternative to marrow for allogeneic transplantation. Lancet 1993; 341: 1482 (letter).
10. Russell NH, Hunter AE. Peripheral blood stem cells for allogeneic transplantation. Bone Marrow Transplant 1994; 13: 353-355.
11. Lane TA, Law P, Maruyama M et al. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. Blood 1995; 85: 275-282.
12. Kessinger A. Smith DM, Strandjord SE et al. Allogeneic transplantation of blood-derived, T-depleted haemopoetic stem cells after myeloablative treatment in a patient with acute lymphoblastic leukemia. Bone Marrow Transplant 1989; 4: 643-646.
13. Mogul MJ, Petersen FB, Meaux LL, Beatty PG. Use of CD34+ positively selected stem cells for allogeneic bone marrow transplant from HLA mismatched relatives. J Cell Biol 1994; 18 (Suppl B): 85 (abstr.).
14. Fritsch G, Fischmeister G, Haas OA et al. Peripheral blood hematopoietic progenitor cells of cytokine-stimulated healthy donors as an alternative for allogeneic transplantation. Blood 1994; 83: 3420-3421 (letter).
15. Dreger P, Haferlach T. Eckstein V et al. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization and composition of the graft. Br J Haematol 1994; 87: 609-613.
16. Russell JA, Luider J, Weaver M et al. Collection of progenitor cells for allogeneic transplantation from peripheral blood of normal donors. Bone Marrow Transplant 1995; 15: 111-115.
17. Nemunaitis J, Rosenfeld C, Collins R et al. Pilot trial of allogeneic transplant combining peripheral blood and bone marrow in patients with refractory hematologic malignancy. Blood 1993; 82 (Suppl.): 1653 (abstr.).
18. Aversa F, Tabilio A, Terenzi A et al. Successful engraftment of T-cell depleted haploidentical 'three loci' incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994; 84: 3948-3955.
19. Schmitz N, Dreger P, Suttorp M et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995; 85: 1666-1672.
20. Bensinger WI, Weaver CH, Appelbaum FR et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony stimulating factor. Blood 1995; 85: 1655-1658.
21. Goldman JM. Peripheral blood stem cells for allografting. Blood 1995; 85: 1413-1416.
22. Bacigalupo A, Majolino I, Van Lint et al. Transplantation of rh-G-CSF mobilized allogeneic peripheral blood cells from HLA identical sibling donors. Bone Marrow Transplant 1995; 15 (Suppl. 2): S5 (abstr.).
23. Körbling M, Przepiorka D, Huh YO et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995; 85: 1659-1665.
24. Russell J, Bowen T, Ruether B et al. Allogeneic transplants for high-risk acute leukemia using blood instead of bone marrow as a source of hemopoietic cells. Exp Hematol 1994; 22: 692 (abstr.).
25. Weaver CH, Buckner CD, Longin K et al. Syngeneic transplantation with peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor. Blood 1993; 82: 1981-1984.
26. Weaver CH, Longin K, Buckner CD, Bensinger W. Lymphocyte content in eripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant 1994; 13: 411-415.
27. Dreger P, Haferlach T, Suttorp M et al. Rapid and sustained engraftment after syngeneic transplantation of G-CSF mobilised peripheral blood progenitor cells. Blood 1993; 82: 630a (abstr.).
28. Russell JA, Poon M-C, Jones AR et al. Allogeneic bone marrow transplantation for adults with malignancy without protective isolation. Lancet 1992; 339: 38-40.
29. Russell JA, Woodman RC, Poon M-C et al. Addition of low-dose folinic acid to a methotrexate/cyclosporin regimen for prevention of acute graft-versus-host disease. Bone Marrow Transplant 1994; 14: 397-401.
30. Gaiger A, Mannhalter C, Hinterberger W et al. Detection of engraftment and mixed chimerism following bone marrow transplantation using PCR amplification of a highly variable region-variable number of tandem repeats (VNTR) in the von willebrand factor gene. Ann Hematol 1991; 63: 227-228.
31. Barrett J, Graft-versus-host disease. In: Treleaven J, Barrett J (eds). Bone Marrow Transplantation in Practice. Churchill Livingstone: Edinburgh, 1992, pp 257-272.
32. Champlin R. T-cell depletion for allogeneic bone marrow transplantation: impact on graft-versus-host disease, engraftment, and graft-versus-leukemia. J Hematother 1993; 2: 27-42.
33. Jansen J, Goselink HH, Veenhof WFJ et al. The impact of the composition of the bone marrow graft on engraftment and graft-versus-host disease. Exp Hematol 1983; 11: 967-973.
34. Atkinson K, Farrell C, Chapman G et al. Female donors increase the risk of acute graft-versus-host disease; effect of donor age and parity and analysis of cell subpopulations in the donor marrow inoculum. Br J Haematol 1986; 63: 231-239.
35. Sullivan KM, Storb R, Buckner CD et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. New Engl J Med 1989; 320: 828-833.
36. Storb R, Doney KC. Thomas ED et al. Marrow transplantation with or without donor buffy coat cells for 65 transfused aplastic anemia patients Blood 1982; 59: 236-246.
37. Antin JH. Graft-versus-leukemia: no longer an epiphenomenon. Blood 1993; 82: 2273-2277.
38. Blaise D, Maraninchi D, Archimbaud E et al. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the Groupe d'Etudes de la Greffe de Moelle Osseuse. Blood 1992; 79: 2578-2582.
39. Devergie A, Blaise D, Attal M et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxantotal body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM). Blood 1995; 85: 2263-2268.
40. Ringdén O, Ruutu T, Remberger M et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic bone marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood 1994; 83: 2723-2730.
41. Bensinger WI, Price TH, Dale DC et al. The effects of daily recombinant granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leucapheresis. Blood 1993; 81: 1883-1888.
42. Casper CB, Seger RA, Burger J, Gmur J. Effective stimulation of donors for granulocyte transfusions with recombinant methionyl granulocyte colony-stimulating factor. Blood 1993; 81: 2866-2871.
43. Buckner CD, Clift RA, Sanders JE et al. Marrow harvesting from normal donors. Blood 1984; 64: 630-634.
44. Stroncek DF, Holland PV, Bartch D et al. Experiences of the first 493 unrelated marrow donors in the National Marrow Donor Program. Blood 1993; 81: 1940-1946.
45. Gisselbrecht C, Prentice HG, Bacigalupo A et al. Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation. Lancet 1994; 343: 696-700.